the type of treatment or therapy being studied. A therapy could range from a medication addressing a particular characteristic of CF to a device or activity e.g. exercise
Restore CFTR Function
A Phase IIa, randomized, double-blind, placebo-controlled study to
evaluate multiple doses of GLPG2222 in subjects with Cystic Fibrosis who are homozygous for the F508del mutation.
Cystic fibrosis is caused by changes in the genes of your DNA (Deoxyribonucleic Acid) encoding for the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) protein. These changes cause the CFTR to stop working as it should. CFTR is a protein present in some specific cells of the body and its correct functioning is important for those cells. GLPG2222 is being studied for treatment of cystic fibrosis. The study drug is designed to improve the amount and function of CFTR, which may improve some of the symptoms of cystic fibrosis.
The purpose of this study is to find out whether GLPG2222, taken by mouth as tablet once a day, is safe, well-tolerated and effective in improving your signs and symptoms of cystic fibrosis.
The study will also evaluate how the body takes in and breaks down the study drug (GLPG2222). The amount of drug in your blood will be measured at specific study visits after you start taking the drug. These measurements will show how quickly the drug is taken up by the body, how quickly it is broken down, when it reaches a steady level in the blood, and how long it stays in the body.
Trial Reference Number
Add to watchlist
Length of participation
the length of time a participant will take part in a trial, from the first to the last appointment
6 - 10 weeks
the name of the treatment or therapy being researched
GLPG2222 or Placebo
the number of participants who need to be recruited for the trial in the UK
Last edited date
01 September 2017
CF sponsor type